Drug Profile
Zelavespib companion diagnostic - Samus Therapeutics
Alternative Names: 124I-PU-H71; Iodine-124-PU-H71; Iodine-124-zelavespib; PU H71 companion diagnostic - Samus Therapeutics; PU H71 PET enhancer; PU H71 positron emission tomography enhancerLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Developer Memorial Sloan-Kettering Cancer Center; Samus Therapeutics
- Class Antineoplastics; Imaging agents; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Cancer(Diagnosis) in USA (IV)
- 31 Jul 2011 Samus Therapeutics obtains a licence to the patent covering PU H71 as a companion diagnostic
- 01 Jul 2011 Memorial Sloan-Kettering Cancer Center initiates enrolment in a phase I trial for Cancer (Diagnosis) and Diagnostic imaging in USA (NCT01393509)